Related Experiment Videos
[Preoperative adjuvant therapy for primary malignant bone tumors]
Takahiro Goto1, Tomotake Okuma, Izumi Nakada
1Dept. of Orthopaedic Surgery and Musculoskeletal Oncology, Tokyo Metropolitan Komagome Hospital, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|November 22, 2007
Summary
Chemotherapy improves outcomes for high-grade bone sarcomas like osteosarcoma and Ewing's sarcoma, but not chondrosarcomas. Preoperative chemotherapy helps shrink tumors and assess drug effectiveness for better surgical results.
Area of Science:
- Oncology
- Orthopedic Surgery
- Medical Chemistry
Context:
- Primary bone sarcomas exhibit variable chemotherapy efficacy based on histology.
- High-grade sarcomas (osteosarcoma, Ewing's sarcoma, MFH) benefit from adjuvant and neoadjuvant chemotherapy.
- Chondrosarcomas and low-grade bone sarcomas are generally chemoresistant or cured by surgery alone.
Purpose:
- To prevent distant metastases in high-grade bone sarcomas.
- To reduce primary tumor size, facilitating less invasive and function-preserving surgery.
- To evaluate chemotherapeutic agent efficacy for informed postoperative treatment selection.
Summary:
- Neoadjuvant chemotherapy is standard for high-grade bone sarcomas, improving prognoses beyond surgery alone.
- Commonly used agents include adriamycin, ifosfamide, and cisplatin for osteosarcoma; vincristine, cyclophosphamide, and etoposide for Ewing's sarcoma.
- Enhanced preoperative chemotherapy strategies like intra-arterial infusion and hyperthermia show promise.
Impact:
- Improved surgical outcomes, including limb- and function-sparing procedures.
- Personalized chemotherapy regimens based on preoperative response.
- Enhanced survival rates for patients with initially poor-prognosis bone sarcomas.